vs
Side-by-side financial comparison of INTERGROUP CORP (INTG) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $17.3M, roughly 1.1× INTERGROUP CORP). SCYNEXIS INC runs the higher net margin — 65.7% vs 8.8%, a 57.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 19.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 7.8%).
Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
INTG vs SCYX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.3M | $18.6M |
| Net Profit | $1.5M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 11.6% | 56.3% |
| Net Margin | 8.8% | 65.7% |
| Revenue YoY | 19.8% | 1808.5% |
| Net Profit YoY | 155.6% | 376.5% |
| EPS (diluted) | $0.71 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.3M | $18.6M | ||
| Q3 25 | $17.9M | $334.0K | ||
| Q2 25 | $16.2M | $1.4M | ||
| Q1 25 | $16.8M | $257.0K | ||
| Q4 24 | $14.4M | $977.0K | ||
| Q3 24 | $16.9M | $660.0K | ||
| Q2 24 | $13.4M | $736.0K | ||
| Q1 24 | $14.9M | $1.4M |
| Q4 25 | $1.5M | $12.3M | ||
| Q3 25 | $-535.0K | $-8.6M | ||
| Q2 25 | $-2.2M | $-6.9M | ||
| Q1 25 | $-578.0K | $-5.4M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-398.0K | $-2.8M | ||
| Q2 24 | $-4.9M | $-14.5M | ||
| Q1 24 | $-3.2M | $411.0K |
| Q4 25 | 11.6% | 56.3% | ||
| Q3 25 | 15.3% | -2516.5% | ||
| Q2 25 | 8.1% | -701.0% | ||
| Q1 25 | 14.0% | -3350.2% | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 18.5% | -1563.6% | ||
| Q2 24 | 3.7% | -1255.0% | ||
| Q1 24 | 4.8% | -692.5% |
| Q4 25 | 8.8% | 65.7% | ||
| Q3 25 | -3.0% | -2572.2% | ||
| Q2 25 | -13.9% | -504.8% | ||
| Q1 25 | -3.4% | -2097.7% | ||
| Q4 24 | -18.9% | — | ||
| Q3 24 | -2.4% | -425.5% | ||
| Q2 24 | -36.7% | -1964.4% | ||
| Q1 24 | -21.3% | 29.9% |
| Q4 25 | $0.71 | $0.25 | ||
| Q3 25 | $-0.25 | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | $-0.27 | $-0.11 | ||
| Q4 24 | $-1.26 | — | ||
| Q3 24 | $-0.18 | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | $-1.44 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.5M | $40.0M |
| Total DebtLower is stronger | $233.2M | — |
| Stockholders' EquityBook value | $-85.2M | $49.4M |
| Total Assets | $101.1M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.5M | $40.0M | ||
| Q3 25 | $6.0M | $37.9M | ||
| Q2 25 | $6.1M | $44.8M | ||
| Q1 25 | $4.8M | $40.6M | ||
| Q4 24 | $15.4M | $59.3M | ||
| Q3 24 | $12.2M | $68.8M | ||
| Q2 24 | $11.6M | $73.0M | ||
| Q1 24 | $19.5M | $80.2M |
| Q4 25 | $233.2M | — | ||
| Q3 25 | $237.8M | — | ||
| Q2 25 | $240.5M | — | ||
| Q1 25 | $241.5M | — | ||
| Q4 24 | $227.2M | — | ||
| Q3 24 | $218.1M | — | ||
| Q2 24 | $225.7M | — | ||
| Q1 24 | $225.0M | — |
| Q4 25 | $-85.2M | $49.4M | ||
| Q3 25 | $-86.7M | $36.4M | ||
| Q2 25 | $-86.1M | $44.5M | ||
| Q1 25 | $-84.5M | $50.5M | ||
| Q4 24 | $-83.9M | $55.1M | ||
| Q3 24 | $-80.9M | $58.5M | ||
| Q2 24 | $-80.3M | $60.4M | ||
| Q1 24 | $-76.4M | $74.1M |
| Q4 25 | $101.1M | $59.0M | ||
| Q3 25 | $102.5M | $51.1M | ||
| Q2 25 | $104.1M | $60.7M | ||
| Q1 25 | $103.2M | $67.9M | ||
| Q4 24 | $110.6M | $90.6M | ||
| Q3 24 | $109.3M | $99.0M | ||
| Q2 24 | $107.8M | $107.8M | ||
| Q1 24 | $119.0M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-23.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-481.0K | — |
| FCF MarginFCF / Revenue | -2.8% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | -0.02× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $739.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-23.0K | $18.4M | ||
| Q3 25 | $-296.0K | $-8.7M | ||
| Q2 25 | $5.9M | $-7.5M | ||
| Q1 25 | $-854.0K | $-7.5M | ||
| Q4 24 | $-781.0K | $-24.0M | ||
| Q3 24 | $3.4M | $765.0K | ||
| Q2 24 | $6.8M | $-10.9M | ||
| Q1 24 | $1.9M | $-4.0M |
| Q4 25 | $-481.0K | — | ||
| Q3 25 | $-1.3M | — | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | $-1.1M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | -2.8% | — | ||
| Q3 25 | -7.1% | — | ||
| Q2 25 | 22.5% | — | ||
| Q1 25 | -6.8% | — | ||
| Q4 24 | -7.8% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 20.4% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 30.4% | — | ||
| Q1 24 | 4.9% | — |
| Q4 25 | -0.02× | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
